The interaction of calcitonin gene-related peptide with angiotensin II on blood pressure and renin release

Itabashi, Akira; Kashiwabara, Hideyuki; Shibuya, Mayumi; Tanaka, Keiko; Masaoka, Hidehiko; Katayama, Shigehiro; Ishii, Jun

doi:10.1097/00004872-198812040-00131

Cited by 21 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings agree well with our in vitro study (17). However, Itabashi et al (33) failed to demonstrate the inhib¬ itory action of CGRP on aldosterone secretion, be¬ cause they used a much larger dose (1 nmol'kg_1-min_1) of CGRP, which induced a marked hypotension and a large increase in PRA. In addition, the discrepancy between the Itabashi study and ours may be due to the responses in ACTH.…”

Section: Discussionsupporting

confidence: 91%

Calcitonin gene-related peptide modulates adrenal hormones in conscious dogs

Murakami

Suzuki²,

Nakamoto³

et al. 1991

Acta Endocrinologica

View full text Add to dashboard Cite

The effects of a small dose (2 pmol/kg) of human calcitonin gene-related peptide I on plasma renin activity and hormones, including, aldosterone, ACTH, cortisol, AVP and ANH, were investigated in 14 conscious dogs. In addition, we studied the effects of calcitonin gene-related peptide on aldosterone secretion when it is stimulated by angiotensin II and ACTH. An intravenous bolus injection of 2 pmol/kg of calcitonin gene-related peptide raised plasma renin activity (by 216%, p<0.05), ACTH (by 85%, p<0.05), AVP (by 89%, p<0.05), and ANH (by 36%, p<0.05). Despite the elevation of plasma renin activity, aldosterone was decreased (by 52%, p<0.05). Cortisol did not change significantly. Infusion of 1 pmol \m=.\kg\m=-\1 \m=.\min\m=-\1of angiotensin II produced an elevation of aldosterone (by 186%, p<0.01), which was completely inhibited by pretreatment with an injection of 2 pmol/kg of calcitonin gene-related peptide. On the other hand, aldosterone secretion stimulated by ACTH was not altered significantly by pretreatment with an injection of 2 pmol/kg of calcitonin gene-related peptide. These results suggest that calcitonin gene-related peptide inhibits aldosterone secretion, especially when aldosterone is stimulated by angiotensin II. In addition, calcitonin gene-related peptide may be involved as an endocrine modulator in the physiological control of other several hormones closely related to the hemodynamics.Calcitonin gene-related peptide (CGRP) is a 37-amino acid polypeptide that results from the tissuespecific processing of the primary RNA transcript of the calcitonin gene (1). CGRP is detected in the systemic circulation (2,3), and the plasma level of CGRP increases during normal human pregnancy (4), in endotoxemia (5) or after sensory nerve injury (6).CGRP has been reported to have a potent vasodilatory action on various isolated vascular tissue preparations (7-9). Intravenous administration of CGRP induced potent dose-related hypotensive and tachycardiac responses in rats and human sub¬ jects (10,11).In addition to its potent vasoactive property, CGRP has an effect on hormonal regulation. CGRP immunoreactivity and specific binding sites for the peptide have been detected in the heart, the adre¬ nal gland, the hypothalamus and the pituitary gland as well as in other organs (12,13). CGRP was shown to stimulate renin secretion both in normal human subjects and in rat renal juxtaglomerular cells (14). More recently CGRP has been found to exhibit stimulatory effects on ANH secretion in vitro in the isolated rat atria (15,16). More recently, we reported that CGRP had an inhibitory action on aldosterone secretion in isolated glomerulosa cells (17). However, possible interaction of CGRP with angiotensin II and ACTH on the adrenal gland in vivo received little attention. Therefore, this study was designed to examine the endocrine responses to intravenous administration of a small dose of CGRP with a specific focus on adrenal hormones, especially aldosterone, in conscious dogs.

show abstract

Section: Discussionsupporting

confidence: 91%

Calcitonin gene-related peptide modulates adrenal hormones in conscious dogs

Murakami

Suzuki²,

Nakamoto³

et al. 1991

Acta Endocrinologica

View full text Add to dashboard Cite

show abstract

“…Growing evidence is indicating that aCGRP and ang II may act reciprocally to help maintain circulatory homeostasis. [21][22][23][24][25] Our results support this hypothesis, indicating that CGRP acts as a functional antagonist of ang II-mediated vasoconstriction and attenuates vasoconstriction in a dosedependent manner. This result is consistent with previous rat model investigations, which found that CGRP inhibits ang II-induced vasoconstriction.…”

Section: Discussionsupporting

confidence: 82%

Calcitonin gene–related peptide inhibits angiotensin II–mediated vasoconstriction in human radial arteries: Role of the Kir channel

Zulli

Wookey

et al. 2008

The Journal of Thoracic and Cardiovascular Surgery

View full text Add to dashboard Cite

show abstract

“…Research in the 1990s focusing on the role of CGRP in blood pressure control was dominated by preclinical hypertension studies carried out in rats that were spontaneously hypertensive (SHR), treated with hypertensive agents, or hypertensive due to surgical intervention. These studies and others reported in vivo evidence that CGRP can protect against hypertension and the vasoconstrictor effects of hypertensive agents including angiotensin-II (AngII) (Itabashi et al, 1988;Fujioka et al, 1991), noradrenaline (Fujioka et al, 1991), deoxycorticosterone-salt (Supowit et al, 1997;Supowit et al, 2005), and the nitric oxide synthase (NOS) inhibitor L-NAME (Gardiner et al, 1991;Gangula et al, 1997), making progress toward understanding the mechanism of action of CGRP (Kumar et al, 2019a). Kawasaki et al (1990) found that reduced CGRP-containing nerves in SHRs contribute to the development and maintenance of hypertension, further supporting a protective role for CGRP in hypertension.…”

Section: Calcitonin Gene-related Peptide In Hypertension -Vascular-de...mentioning

confidence: 93%

The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease

Argunhan

Brain

2022

Front. Physiol.

View full text Add to dashboard Cite

The treatment of hypertension and heart failure remains a major challenge to healthcare providers. Despite therapeutic advances, heart failure affects more than 26 million people worldwide and is increasing in prevalence due to an ageing population. Similarly, despite an improvement in blood pressure management, largely due to pharmacological interventions, hypertension remains a silent killer. This is in part due to its ability to contribute to heart failure. Development of novel therapies will likely be at the forefront of future cardiovascular studies to address these unmet needs. Calcitonin gene-related peptide (CGRP) is a 37 amino acid potent vasodilator with positive-ionotropic and -chronotropic effects. It has been reported to have beneficial effects in hypertensive and heart failure patients. Interestingly, changes in plasma CGRP concentration in patients after myocardial infarction, heart failure, and in some forms of hypertension, also support a role for CGRP on hemodynamic functions. Rodent studies have played an important role thus far in delineating mechanisms involved in CGRP-induced cardioprotection. However, due to the short plasma half-life of CGRP, these well documented beneficial effects have often proven to be acute and transient. Recent development of longer lasting CGRP agonists may therefore offer a practical solution to investigating CGRP further in cardiovascular disease in vivo. Furthermore, pre-clinical murine studies have hinted at the prospect of cardioprotective mechanisms of CGRP which is independent of its hypotensive effect. Here, we discuss past and present evidence of vascular-dependent and -independent processes by which CGRP could protect the vasculature and myocardium against cardiovascular dysfunction.

show abstract

The interaction of calcitonin gene-related peptide with angiotensin II on blood pressure and renin release

Cited by 21 publications

References 0 publications

Calcitonin gene-related peptide modulates adrenal hormones in conscious dogs

Calcitonin gene-related peptide modulates adrenal hormones in conscious dogs

Calcitonin gene–related peptide inhibits angiotensin II–mediated vasoconstriction in human radial arteries: Role of the Kir channel

The Vascular-Dependent and -Independent Actions of Calcitonin Gene-Related Peptide in Cardiovascular Disease

Contact Info

Product

Resources

About